At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02197 CLOVER BIO-B
Trading 04-24 11:32:51
2.960
-0.100
-3.27%
High3.000Low2.950Vol1.02M
Open3.000D1 Closing3.060Amplitude1.63%
Mkt Cap3.84BTradable Cap3.84BTotal Shares1.30B
T/O3.04MT/O Rate0.08%Tradable Shares1.30B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
三叶草生物医药：2025年经营亏损显著收窄，呼吸道疫苗管线持续推进
Bulletin Express  ·  04-23 19:09
三叶草生物医药：2025年经营亏损显著收窄，呼吸道疫苗管线持续推进
Clover Biopharma Reminds Non-Registered Shareholders of Shift to Electronic Dissemination of Corporate Communications
Bulletin Express  ·  04-23 19:05
Clover Biopharma Reminds Non-Registered Shareholders of Shift to Electronic Dissemination of Corporate Communications
Clover Biopharmaceuticals Implements Full Electronic Dissemination of Corporate Communications, Seeks Shareholders’ Email Details
Bulletin Express  ·  04-23 19:03
Clover Biopharmaceuticals Implements Full Electronic Dissemination of Corporate Communications, Seeks Shareholders’ Email Details
Cellectar CLOVER-WaM trial data accepted for ASCO 2026 poster presentation
Reuters  ·  04-21 22:01
Cellectar CLOVER-WaM trial data accepted for ASCO 2026 poster presentation
Clover BioPharma Adds 1,000 Shares via Option Exercise; Outstanding Post-IPO Options Rise to 42.85 Million
Bulletin Express  ·  04-09
Clover BioPharma Adds 1,000 Shares via Option Exercise; Outstanding Post-IPO Options Rise to 42.85 Million
CLOVER BIO-B Shares Surge Over 7% Again on Progress in Respiratory Combo Vaccine Trial
Stock News  ·  04-09
CLOVER BIO-B Shares Surge Over 7% Again on Progress in Respiratory Combo Vaccine Trial
Clover Bio clarifies Gavi settlement terms, caps future payments at US$58 million
Reuters  ·  04-02
Clover Bio clarifies Gavi settlement terms, caps future payments at US$58 million
Clover Completes Enrollment of 420 Participants in Australian Phase 2 Trial for RSV-hMPV ± PIV3 Vaccine Candidates
Bulletin Express  ·  03-30
Clover Completes Enrollment of 420 Participants in Australian Phase 2 Trial for RSV-hMPV ± PIV3 Vaccine Candidates
Clover Biopharmaceuticals Completes Enrollment for Australian Phase II Trial of Combined Respiratory Vaccine Candidate
Stock News  ·  03-30
Clover Biopharmaceuticals Completes Enrollment for Australian Phase II Trial of Combined Respiratory Vaccine Candidate
Clover completes enrollment in Australia Phase 2 trial for RSV combination vaccine candidates
Reuters  ·  03-30
Clover completes enrollment in Australia Phase 2 trial for RSV combination vaccine candidates
Clover Bio Grants 10.20 Million Stock Options and 8.97 Million RSUs to Directors and Employees
Bulletin Express  ·  03-27
Clover Bio Grants 10.20 Million Stock Options and 8.97 Million RSUs to Directors and Employees
CLOVER BIO-B Grants 10.1955 Million Share Options and 8.965 Million Restricted Share Units
Stock News  ·  03-27
CLOVER BIO-B Grants 10.1955 Million Share Options and 8.965 Million Restricted Share Units
Clover Biopharmaceuticals grants 10.2 million options; RSUs climb to 9.0 million
Reuters  ·  03-27
Clover Biopharmaceuticals grants 10.2 million options; RSUs climb to 9.0 million
Stock Track | CLOVER BIO-B Soars 5.32% Intraday as Annual Results Show Net Loss Narrowed 77.3%
Stock Track  ·  03-26
Stock Track | CLOVER BIO-B Soars 5.32% Intraday as Annual Results Show Net Loss Narrowed 77.3%
Stock Track | Clover Bio-B Plummets 5.32% Intraday After Annual Results Show 90.9% Revenue Drop
Stock Track  ·  03-26
Stock Track | Clover Bio-B Plummets 5.32% Intraday After Annual Results Show 90.9% Revenue Drop
CLOVER BIO-B Reports Annual Results: Net Loss Narrows 77.3% to RMB205 Million
Stock News  ·  03-26
CLOVER BIO-B Reports Annual Results: Net Loss Narrows 77.3% to RMB205 Million
Clover Biopharmaceuticals FY2025 loss narrows 77.3% to RMB205 million; revenue drops 90.9% to RMB3.5 million
Reuters  ·  03-26
Clover Biopharmaceuticals FY2025 loss narrows 77.3% to RMB205 million; revenue drops 90.9% to RMB3.5 million
Clover Biopharmaceuticals Ltd - Loss for Year RMB205.1 Mln
THOMSON REUTERS  ·  03-26
Clover Biopharmaceuticals Ltd - Loss for Year RMB205.1 Mln
Stock Track | Clover Bio-B Soars 6.99% Intraday on Positive Phase I RSV Vaccine Data Showing 60-80% Superiority Over GSK's Arexvy
Stock Track  ·  03-25
Stock Track | Clover Bio-B Soars 6.99% Intraday on Positive Phase I RSV Vaccine Data Showing 60-80% Superiority Over GSK's Arexvy
Clover Biopharmaceuticals’ SCB-1019 Generates 60–80% Higher RSV Neutralizing Antibodies than GSK’s AREXVY in U.S. Revaccination Trial
Bulletin Express  ·  03-25
Clover Biopharmaceuticals’ SCB-1019 Generates 60–80% Higher RSV Neutralizing Antibodies than GSK’s AREXVY in U.S. Revaccination Trial

Introduction

Company Name.
CLOVER BIO-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Clover Biopharmaceuticals Ltd is an investment holding company primarily engaged in the research and development, manufacture and commercialization of innovative vaccines. The Company’s products and candidates include Respiratory Syncytial Virus (RSV) Vaccine (SCB-1019), seasonal quadrivalent influenza vaccine AdimFlu-S, SCB-219M, COVID-19 Vaccine and others. The Company leverages the Trimer-Tag technology platform to conduct research and development (R&D) for innovative vaccines that can fulfill unmet need, with a focus on building a respiratory vaccine franchise and establishing a presence in the pediatric vaccine market. The Trimer-Tag is a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets. The Company conducts its business in the domestic and overseas markets.
Issue price:
--